Market Size of Germany Insulin Drugs And Delivery Devices Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
Market Size (2024) | USD 1.10 Billion |
Market Size (2029) | USD 1.13 Billion |
CAGR (2024 - 2029) | 0.50 % |
Major Players*Disclaimer: Major Players sorted in no particular order |
Germany Insulin Drugs And Delivery Devices Market Analysis
The Germany Insulin Drugs And Delivery Devices Market size is estimated at USD 1.10 billion in 2024, and is expected to reach USD 1.13 billion by 2029, growing at a CAGR of 0.5% during the forecast period (2024-2029).
One of the most significant risk factors for a severe course of COVID-19 is diabetes mellitus. This risk is believed to be influenced by several variables that are frequently present in diabetes mellitus, such as advanced age, a proinflammatory and hypercoagulable condition, hyperglycemia, and underlying comorbidities (hypertension, cardiovascular disease, chronic kidney disease, and obesity). Diabetes was quickly recognized as a risk factor for bad results during the COVID-19 pandemic. That's why managing or delaying cases of type 2 diabetes became more important than ever before. Several studies have confirmed that chronic diseases like diabetes are associated with adverse outcomes in COVID-19 patients.
Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and, thus, incur more healthcare expenses compared to non-diabetic people. People with diabetes face a higher chance of experiencing serious complications from COVID-19. In general, people with diabetes are more likely to experience severe symptoms and complications when infected with a virus. Diabetes and high glucose levels are associated with increased complications, respiratory failure, and mortality in hospitalized patients with coronavirus.
Germany is one of the developed countries and advanced in terms of healthcare facilities. Technologies, such as continuous glucose monitoring and insulin infusion pumps, are getting more adopted rapidly in Germany than the other developing countries. Moreover, the reimbursement policy and the pricing policy are highly regulated, which drives the market and increases the adoption rate of new and advanced technologies. The pandemic also highlighted opportunities for continuing and expanding innovations in the delivery of diabetes care, through virtual consultations between healthcare providers and people with diabetes, and the use of diabetes technology. Crisis management has created unprecedented interest in remote care from both patients and providers and removed many long-standing regulatory barriers. Thus, the COVID-19 outbreak increased the insulin market's growth.
Germany Insulin Drugs And Delivery Devices Industry Segmentation
Insulin is mainly used to treat type 1 diabetes but can be used in people with type 2 diabetes if insulin levels remain low despite using other medications. There are different ways to inject insulin into a patient's body, using syringes, pens, pumps, and jet injectors, giving them various options for insulin delivery. The Germany Insulin Drugs and Delivery Devices Market is segmented into Drugs (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins), Devices (Insulin Pens, Insulin Pumps, Insulin Syringes, and Jet Injectors). The report offers the value (in USD million) and volume (in million mL) for insulin drugs and (in unit million) for the devices for the above segments.
Drug | |||||||||
| |||||||||
| |||||||||
| |||||||||
| |||||||||
|
Device | |||||
| |||||
| |||||
Insulin Syringes | |||||
Insulin Jet Injectors |
Germany Insulin Drugs And Delivery Devices Market Size Summary
The Germany Insulin Drugs and Delivery Devices Market is poised for steady growth, driven by the increasing prevalence of diabetes and the adoption of advanced healthcare technologies. The market is characterized by a robust healthcare infrastructure that supports the rapid integration of innovations such as continuous glucose monitoring and insulin infusion pumps. These technologies are gaining traction due to their ability to offer more precise and convenient insulin delivery compared to traditional methods. The regulatory environment in Germany, with its stringent reimbursement and pricing policies, further facilitates the adoption of these advanced solutions, ensuring that diabetes patients have access to necessary treatments with minimal out-of-pocket expenses. This supportive framework is encouraging companies to invest in the development of innovative products, thereby enhancing the market's growth prospects.
The insulin delivery devices segment, particularly insulin pumps, is expected to maintain a significant market share, benefiting from technological advancements and their preference over traditional delivery systems. Insulin pumps offer numerous advantages, such as reducing blood glucose level fluctuations and minimizing pain, which are expected to drive their adoption. The market is moderately consolidated, with key players like Medtronic, Ypsomed, Novo Nordisk, Eli Lilly, and Sanofi Aventis actively engaging in collaborations and strategic partnerships to strengthen their market presence. These collaborations aim to enhance insulin therapy solutions and explore potential drug candidates for diabetes treatment, further contributing to the market's expansion. As the diabetes population in Germany continues to grow, the market for insulin drugs and delivery devices is anticipated to experience sustained growth over the forecast period.
Germany Insulin Drugs And Delivery Devices Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.3 Market Restraints
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products and Services
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 Drug
-
2.1.1 Basal or Long-acting Insulins
-
2.1.1.1 Lantus (Insulin Glargine)
-
2.1.1.2 Levemir (Insulin Detemir)
-
2.1.1.3 Toujeo (Insulin Glargine)
-
2.1.1.4 Tresiba (Insulin Degludec)
-
2.1.1.5 Basaglar (Insulin Glargine)
-
2.1.1.5.1 Other drugs
-
-
-
2.1.2 Bolus or Fast-acting Insulins
-
2.1.2.1 NovoRapid/Novolog (Insulin aspart)
-
2.1.2.2 Humalog (Insulin lispro)
-
2.1.2.3 Apidra (Insulin glulisine)
-
2.1.2.4 FIASP (Insulin aspart)
-
2.1.2.5 Admelog (Insulin lispro Sanofi)
-
-
2.1.3 Traditional Human Insulins
-
2.1.3.1 Novolin/Mixtard/Actrapid/Insulatard
-
2.1.3.2 Humulin
-
2.1.3.3 Insuman
-
-
2.1.4 Combination Insulins
-
2.1.4.1 NovoMix (Biphasic Insulin aspart)
-
2.1.4.2 Ryzodeg (Insulin degludec and Insulin aspart)
-
2.1.4.3 Xultophy (Insulin degludec and Liraglutide)
-
2.1.4.4 Soliqua/Suliqua (Insulin glargine and Lixisenatide)
-
-
2.1.5 Biosimilar Insulins
-
2.1.5.1 Insulin Glargine Biosimilars
-
2.1.5.2 Human Insulin Biosimilars
-
-
-
2.2 Device
-
2.2.1 Insulin Pumps
-
2.2.1.1 Insulin Pump Devices
-
2.2.1.2 Insulin Pump Reservoirs
-
2.2.1.3 Insulin Infusion sets
-
-
2.2.2 Insulin Pens
-
2.2.2.1 Cartridges in reusable pens
-
2.2.2.2 Disposable insulin pens
-
-
2.2.3 Insulin Syringes
-
2.2.4 Insulin Jet Injectors
-
-
Germany Insulin Drugs And Delivery Devices Market Size FAQs
How big is the Germany Insulin Drugs And Delivery Devices Market?
The Germany Insulin Drugs And Delivery Devices Market size is expected to reach USD 1.10 billion in 2024 and grow at a CAGR of 0.5% to reach USD 1.13 billion by 2029.
What is the current Germany Insulin Drugs And Delivery Devices Market size?
In 2024, the Germany Insulin Drugs And Delivery Devices Market size is expected to reach USD 1.10 billion.